FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 3,440,000 shares, a decrease of 11.8% from the November 15th total of 3,900,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 2.9 days.

FibroGen Stock Performance

Shares of NASDAQ:FGEN traded down $0.01 during midday trading on Friday, hitting $0.33. 1,107,400 shares of the stock were exchanged, compared to its average volume of 2,125,624. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The business’s fifty day simple moving average is $0.35 and its two-hundred day simple moving average is $0.59. The company has a market capitalization of $33.55 million, a PE ratio of -0.27 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the business posted ($0.52) earnings per share. As a group, equities analysts anticipate that FibroGen will post -0.86 EPS for the current year.

Hedge Funds Weigh In On FibroGen

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares during the last quarter. FMR LLC increased its position in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in FibroGen during the third quarter worth $307,000. Point72 DIFC Ltd increased its position in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares during the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on FGEN shares. StockNews.com started coverage on FibroGen in a report on Sunday, December 8th. They issued a “hold” rating for the company. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.